Drug intelligence / Profile preview

GM500

Development stage: Preclinical
Lead developer: GlycoMantra
Modality: Small Molecules
Administration: Oral

Overview

GM500 is a small molecule drug candidate developed by GlycoMantra for the treatment of colorectal cancer. As part of GlycoMantra's focus on galectin-based therapies, GM500 is designed to inhibit Galectin-3, a beta-galactoside-binding lectin that is frequently overexpressed in the colorectal tumor microenvironment. Galectin-3 contributes to immune evasion, promotes angiogenesis, and facilitates metastasis; by antagonizing this protein, GM500 aims to suppress tumor progression. The drug is currently in the early stages of development, potentially offering an oral delivery profile as a small molecule antagonist.

Targets

LGALS3 (Galectin-3)

Beyond the preview

Go deeper on GM500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM500.

Explore the full profile